Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has reported its financial results for the first half of 2026, revealing a significant increase in revenue and the advancement of an expanded clinical manufacturing program for a U.S.-based biopharmaceutical company. The company, which combines therapeutic development with a revenue-generating contract development and manufacturing organization (CDMO), posted first-half revenue of $949,000, up from $773,000 in the same period last year. Committed customer orders reached approximately $3.1 million as of Aug. 16, 2026, including about $2.1 million already invoiced, indicating strong demand for its CDMO services.
One of the key highlights is the ongoing expansion of a clinical manufacturing and chemistry, manufacturing, and controls (CMC) program for a U.S. biopharmaceutical client. Scinai has received approximately $650,000 in cash payments and advances, with substantive activities already underway. While a definitive agreement is still under negotiation, the program is intended to support an investigational drug product toward a U.S. investigational new drug (IND) submission and Phase III clinical development. This move underscores Scinai's strategic focus on expanding its CDMO footprint and capitalizing on the growing need for specialized manufacturing services in the biotech sector. The company continues to pursue approximately $5 million in CDMO revenue for 2026.
Financially, Scinai reported an operating loss of $4.6 million for the first half, compared to a loss of $3.8 million in the prior-year period. However, net income swung to a positive $1.6 million, versus a net loss of $4.1 million a year earlier, primarily due to a $6.4 million bargain purchase gain from the acquisition of Recipharm Israel. As of June 30, 2026, the company held approximately $2.9 million in cash, cash equivalents, and restricted cash. These figures reflect a period of strategic investment and growth, as the company balances its operational losses with strategic gains.
Beyond its CDMO business, Scinai continues to advance its therapeutic programs, including PC111 and NanoAbs, which are part of its pipeline of innovative immunology therapies licensed from the Max Planck Society and PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., which provides development and manufacturing services through facilities in Jerusalem and Yavne, Israel. To discuss these developments and upcoming milestones, Scinai will host an investor webinar on Aug. 26, 2026.
The importance of this news lies in Scinai's dual business model, which not only develops its own therapies but also generates revenue through its CDMO services. This approach provides a financial buffer while advancing potentially groundbreaking treatments. The expansion of the U.S. clinical manufacturing program signals increased trust from biopharmaceutical companies in Scinai's capabilities, potentially leading to more contracts and revenue growth. For investors and the biotech industry, Scinai's progress offers a glimpse into how integrated development and manufacturing can drive value. As the company moves toward its 2026 revenue goals, its ability to secure and execute such programs will be critical. The full press release is available at https://nnw.fm/Be7Ky, and updates on the company can be found at https://nnw.fm/SCNI.
